LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 97 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,371 | -6.0% | 972 | 0.0% | 0.00% | – |
Q1 2023 | $1,458 | -95.8% | 972 | -93.0% | 0.00% | – |
Q3 2021 | $35,000 | +250.0% | 13,807 | +34.3% | 0.00% | – |
Q3 2020 | $10,000 | +11.1% | 10,279 | 0.0% | 0.00% | – |
Q2 2020 | $9,000 | 0.0% | 10,279 | 0.0% | 0.00% | – |
Q1 2020 | $9,000 | -40.0% | 10,279 | -40.2% | 0.00% | – |
Q4 2019 | $15,000 | – | 17,179 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,005,379 | $28,160,000 | 3.29% |
Defender Capital, LLC. | 4,416,590 | $3,657,000 | 2.67% |
Prescott General Partners LLC | 1,851,851 | $1,534,000 | 0.13% |
Laidlaw Wealth Management LLC | 107,379 | $89,000 | 0.06% |
Northeast Financial Consultants Inc | 523,756 | $434,000 | 0.05% |
Beirne Wealth Consulting Services, LLC | 45,000 | $37,000 | 0.04% |
DAFNA Capital Management LLC | 95,000 | $79,000 | 0.03% |
Summit X, LLC | 30,700 | $25,000 | 0.01% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 529,039 | $438,000 | 0.01% |
Keudell/Morrison Wealth Management | 10,105 | $8,000 | 0.01% |